Amrita Krishnan

Jan 13, 2025 | ajmc.com | Amrita Krishnan

OpinionVideoJanuary 13, 2025Author(s):Amrita Krishnan, MD, discusses how data from ASH 2024 highlight the critical role of intravenous immunoglobulin (IVIG) treatment in preventing infections in patients receiving teclistamab, shares her approach to incorporating IVIG into clinical practice, and outlines additional strategies for reducing infection risk and managing cytokine release syndrome (CRS) in patients on bispecific antibody therapies for multiple myeloma.

Jan 13, 2025 | ajmc.com | Amrita Krishnan

OpinionVideoJanuary 13, 2025Author(s):Amrita Krishnan, MD, discusses how an ASH 2024 abstract from Sylvester Comprehensive Cancer Center suggests the potential of tocilizumab prophylaxis to mitigate cytokine release syndrome (CRS) in patients treated with bispecific therapies for multiple myeloma, and shares her approach to managing unique toxicities such as nail changes, skin reactions, and oral complications in patients receiving talquetamab.

Oct 11, 2024 | onclive.com | Amrita Krishnan

CommentaryVideoOctober 11, 2024Author(s):Fact checked by:Amrita Krishnan, MD, discusses the role of DKd for patients with relapsed/refractory multiple myeloma.

Aug 29, 2024 | onclive.com | Amrita Krishnan

Amrita Krishnan, MD, executive medical director, Hematology, City of Hope Orange County; director, the Judy and Bernard Briskin Multiple Myeloma Center; professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses maintenance therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma, and how factors such as minimal residual disease (MRD) negativity factor into treatment decision-making.

Aug 23, 2024 | onclive.com | Amrita Krishnan

CommentaryVideoAugust 23, 2024Author(s):Amrita Krishnan, MD, discusses the potential role for cilta-cel in early-relapsed, high-risk patients with multiple myeloma.